6 results about "Low-substituted hydroxypropylcellulose" patented technology

A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.

The present invention relates to a novel formulation comprising a benzimidazole derivative. The formulation for oral administration comprising a compound of Formula 1 according to the present invention or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose, exhibits an excellent storage stability and has an effect on preventing a phenomenon of decline in dissolution rate, thus being usefully used as a formulation for oral administration.

The invention discloses peimisine for inhibiting gastric cancer as well as application and a composition thereof, and relates to the technical field of application of peimisine compositions. The peimisine has the effect of inhibiting gastric cancer by inhibiting a PI3K / Akt signal channel. The preparation method comprises the following steps: mixing pregelatinized starch, a composite auxiliary material, lactose and a peimisine microcapsule, adding polyethylene glycol, sodium carboxymethyl starch and low-substituted hydroxy propyl cellulose, mixing, and tabletting to obtain the peimisine microcapsule tablet. The application proves that peimisine can be used for inhibiting gastric cancer, and peimisine micro-capsule tablets prepared from the composition of peimisine can form pH responsive release, reduce gastric mucosa stimulation, improve bioavailability and facilitate absorption of peimisine.

To provide a method for producing highly stable tablets containing Selexipag.SOLUTION: According to one embodiment of the present invention, there is provided a method for producing tablets containing Selexipag, comprising granulating additives to produce a granulated product, mixing the granulated product with Selexipag to obtain a mixture, and tableting the mixture, wherein the granulated product does not substantially contain Selexipag in the method for producing tablets containing Selexipag. The additive in the granulated product may include at least one selected from the group consisting of D-mannitol, hydroxypropyl cellulose, and low-substituted hydroxypropyl cellulose.SELECTED DRAWING: None

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cilostazol controlled-release preparation and a preparation method thereof. The preparation is based on a composite carrier composed of mesoporous silica and low-substituted hydroxy propyl cellulose, the cilostazol is highly dispersed in the composite carrier in an amorphous state through combination of ball milling pretreatment and a high-temperature fluidized bed melt dispersion process, and a final tablet is obtained through tabletting by adopting a step-by-step design of internally and externally adding a disintegrating agent. The dissolution rate of the cilostazol preparation prepared by the invention is greater than or equal to 80% within 15 minutes and greater than or equal to 95% within 30 minutes, so that rapid and stable drug release is realized, and the risk of burst release of the drug and adverse reaction caused by fluctuation of blood concentration are effectively reduced; and the preparation shows excellent stability, and an acceleration test (6 months) result shows that the increase of related substances of the preparation is less than or equal to 0.5%, the change rate of the dissolution rate is less than or equal to 3%, and the consistency and reliability of the curative effect in the clinical medication process can be effectively guaranteed.

To provide an apremilast solid preparation suppressed in increase of related substances with time and excellent in stability.SOLUTION: The apremilast solid preparation contains apremilast and an additive, wherein the additive contains at least one selected from the group consisting of low-substituted hydroxypropyl cellulose, crospovidone, glycerin fatty acid ester, hydrous silicon dioxide, and light anhydrous silicic acid. It is preferable that the additive does not contain at least one selected from the group consisting of a sodium salt, a calcium salt, and a magnesium salt.SELECTED DRAWING: None